Prostatis Group’s Capital One COF Stock Holding History

Prostatis Group’s Portfolio COF Stock Details COF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,694	Closed	-$491K	–	192
2026 Q1	$491K	Buy	2,694 +801	+42%	+$168K	0.13%	104
2025 Q4	$459K	Buy	+1,893	New	+$421K	0.11%	107

Other funds holding COF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Prostatis Group's COF Position: Q2 2026 in Review

Prostatis Group sold out of Capital One (COF) in Q2 2026, closing a stake of 2,694 shares — an estimated $491K sold.

Prostatis Group first reported a position in COF in Q4 2025 and held it in 2 quarters. The position peaked at $491K in Q1 2026. 2,118 funds tracked by Wall St. Rank hold COF as of Q2 2026.

Prostatis Group reported no remaining Capital One position as of Q2 2026 after selling out during the quarter.
Prostatis Group sold 2,694 Capital One shares in Q2 2026, an estimated $491K.
Prostatis Group first reported a position in Capital One in Q4 2025 and held it in 2 quarters.
Prostatis Group's Capital One position peaked at $491K in Q1 2026.
2,118 funds tracked by Wall St. Rank held Capital One as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.